ARCH Venture Discloses 25.6% Stake in City Therapeutics After $30M IPO-Era Buying
CTY is trading near its 52-week low of $19.75 (5.3% above the low) on light trading volume (0.3× avg).
Summary
ARCH Venture Fund XII disclosed a 25.6% stake in newly public City Therapeutics — 13,692,507 shares costing $30.06M in total — with the position locked up for 180 days from the October 15 IPO.
Key Events · Ownership and Investor Activity · CTY
-
ARCH Discloses 25.6% Stake
ARCH Venture Fund XII reports beneficial ownership of 13,692,507 shares, or 25.6% of the 53,387,834 shares outstanding following the IPO.
-
$30.06M Total Purchase Cost
Total paid was $30,059,985.76: 2,027,006 Series B preferred shares at $13.3201 (split-adjusted, converted to common at the IPO close) plus 170,000 IPO shares at $18.00 from the underwriters.
-
180-Day Lock-Up Until April 2027
AVF XII agreed not to sell or transfer its shares for 180 days after October 15, 2026, absent written consent from Goldman Sachs and Jefferies.
-
Registration Rights Survive IPO
The Investor Rights Agreement keeps demand, piggyback and shelf registration rights; financial-statement, inspection, observer and rights-of-first-offer covenants terminated at the IPO close.
Analysis · CTY · Life Sciences
A concentrated sponsor stake now has hard numbers. ARCH Venture Fund XII reports beneficial ownership of 13,692,507 shares, or 25.6% of City Therapeutics' 53,387,834 post-IPO shares, in a company that just went public at $18 on October 15. The filing quantifies what the Form 4s only sketched: $30,059,985.76 total paid, combining a May 2026 Series B purchase at $13.3201 per share (2,027,006 shares, split-adjusted) with 170,000 IPO shares bought from the underwriters at $18.00. For holders, the practical constraint is the 180-day lock-up from October 15, 2026, which keeps those shares off the market until roughly mid-April 2027 unless Goldman Sachs and Jefferies consent to an early release. ARCH also retains demand, piggyback and shelf registration rights, so a path to registering the shares for resale exists once the lock-up lapses. The filing states the shares were acquired for investment purposes with no present plans for the transactions listed in Item 4.
How filings like this one have moved
In the 30 days to Oct 27, 2026, 29.9% of the 1374 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTY was trading at $20.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $19.75 to $23.88. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.